Last reviewed · How we verify
Nicotine Lozenge
Nicotine Lozenge, marketed by Fred Hutchinson Cancer Center, holds a position in the smoking cessation market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Nicotine Lozenge |
|---|---|
| Also known as | Nicorette, mini lozenge, Nicotine Polacrilex lozenge, Commite Nicotine lozenge, Commit |
| Sponsor | Fred Hutchinson Cancer Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers (NA)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |